GSK and Janssen wade into competitive RA market with Phase III sirukumab program
This article was originally published in Scrip
GlaxoSmithKline and Janssen Biologics kicked off the Phase III program for their interleukin-6 (IL-6) inhibitor sirukumab (CNTO 136), which would compete with relative newcomers in the competitive rheumatoid arthritis market – Genentech's Actemra (tocilizumab), the first IL-6 inhibitor approved to treat patients with moderately to severely active rheumatoid arthritis, and Pfizer's novel oral Janus kinase (JAK) inhibitor tofacitinib.
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science.
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.